Anti-Human IL 12/23 (Briakinumab)Anti-Human IL 12/23 (Briakinumab)
Move your mouse over image or click to enlarge

Anti-Human IL 12/23 (Briakinumab)

Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Cat# Size Price Qty Buy
LT500-100mg 100 mg
£4,781.25
LT500-50mg 50 mg
£3,515.63
LT500-25mg 25 mg
£2,296.88
LT500-5.0mg 5.0 mg
£609.38
LT500-1.0mg 1.0 mg
£164.06

Additional Information

Property Value or Rating
Manufacturer Cat# LT500
Concentration ≥ 5.0 mg/ml
Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Manufacturer Leinco Technologies Inc
Isotype IgG1 λ
Clone ABT-874
Applications B, ELISA, FA, FC, IF, IP, N, WB
Antigen IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.
Storage Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Protein IL-12/IL-23 p40

Related Documents